Severe late onset capillary leak syndrome post allo-HSCT successfully treated by bevacizumab: a case report

Severe late onset capillary leak syndrome post allo-HSCT successfully treated by bevacizumab: a case report

This article describes a case of successful management of late-onset CLS occurring after allo-HSCT, employing bevacizumab as the therapeutic agent. Capillary leak syndrome (CLS) represents a critical complication arising from allogeneic hematopoietic stem cell transplantation (allo-HSCT). The progno...

Full description

Saved in:
Bibliographic Details
Main Authors: Song Xue, Jiaqi Chen, Yuzhu Shi, Lina Zhang, Man Chen, Huipeng Sun, Xingyu Cao, Fang Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Medicine
Subjects:
capillary leak syndrome (CLS)
allo-HSCT
bevacizumab (avastin)
case report
vascular endothelial growth factor (VEGF)
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2024.1483064/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This article describes a case of successful management of late-onset CLS occurring after allo-HSCT, employing bevacizumab as the therapeutic agent. Capillary leak syndrome (CLS) represents a critical complication arising from allogeneic hematopoietic stem cell transplantation (allo-HSCT). The prognosis for CLS remains considerably constrained. A targeted therapeutic approach targeting vascular endothelial growth factor (VEGF) offers a novel strategy for the management of CLS.
ISSN:2296-858X

Similar Items